2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 504

Influence of CDAI Measurement on the Decision of Community Rheumatologists to Initiate or Change Biologic Treatment
Abstract Number: 2091

Influence of Increasing Physical Activity on Longitudinal Changes in Disability Status Among Inactive Older Adults
Abstract Number: 90

Influence of Susceptible HLA-DRB1 Alleles on Clinical Subphenotypes of Systemic Lupus Erythematosus in Koreans
Abstract Number: 7

Influence of TNF on Anti-Inflammatory Tyrosine-Hydroxylase-Positive Synovial Cells in Rheumatoid Arthritis and Osteoarthritis
Abstract Number: 2104

Influence on Treatment Decision Making of Providing Numerical Ranges of Side-Effect Risks
Abstract Number: 2964

Influences of Various Factors on Survival of Patients Treated with Pulmonary Arterial Hypertension-Specific Drugs Combination Therapy in Patients with Connective Tissue Diseases
Abstract Number: 1107

Inhibition of B Cell Activation and Plasma Cell Differentiation By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
Abstract Number: 2205

Inhibition of Dickkopf1 Dampens Anti Osteogenic Effect of Fibroblast-like Synoviocytes
Abstract Number: 2154

Inhibition of Gli Ameliorates the Pro-Fibrotic Effects of Transforming Growth Factor-Î² in Systemic Sclerosis
Abstract Number: 2554

Inhibition of IL6 Receptor Improves Arthritis and Atherosclerosis in a Mouse Model of Rheumatoid Arthritis
Abstract Number: 3188

Inhibition of Lymphatic Muscle Contraction By Lymphatic Endothelial iNOS Impairs Lymph Drainage from Arthritic Joints in TNF-Tg Mice and Is Prevented By Herbal Drugs
Abstract Number: 2086

Inhibition of Macrophage Inflammatory Protein 1-Alpha (CCL3) Significantly Reduced Bone Resorption in Vitro and the Development of Erosive Joint Pathology in Collagen-Induced Arthritis
Abstract Number: 2151

Inhibition of Myeloid-Associated Gene Expression in Skin Biopsy Samples of Systemic Sclerosis Patients Treated with Tocilizumab
Abstract Number: 1907

Inhibition of Phosphodiesterase 4 (PDE4) Reduces Dermal Fibrosis By Interfering with the Release of Pro-Fibrotic Cytokines from M2-Macrophages
Abstract Number: 2155

Inhibition of Sphingosine-1-Phosphate Signaling By AB22 As a Novel Strategy in the Treatment of Pulmonary Fibrosis Associated with Scleroderma

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].